Literature DB >> 23794798

In Vivo Replication and Pathogenesis of Vesicular Stomatitis Virus Recombinant M40 Containing Ebola Virus L-Domain Sequences.

Takashi Irie1, Elena Carnero, Adolfo García-Sastre, Ronald N Harty.   

Abstract

The M40 VSV recombinant was engineered to contain overlapping PTAP and PPxY L-domain motifs and flanking residues from the VP40 protein of Ebola virus. Replication of M40 in cell culture is virtually indistinguishable from that of control viruses. However, the presence of the Ebola PTAP motif in the M40 recombinant enabled this virus to interact with and recruit host Tsg101, which was packaged into M40 virions. In this brief report, we compared replication and the pathogenic profiles of M40 and the parental virus M51R in mice to determine whether the presence of the Ebola L-domains and flanking residues altered in vivo characteristics of the virus. Overall, the in vivo characteristics of M40 were similar to those of the parental M51R virus, indicating that the Ebola sequences did not alter pathogenesis of VSV in this small animal model of infection.

Entities:  

Keywords:  Ebola; L-domain; VSV; animal model; budding; pathogenesis; recombinant virus

Year:  2012        PMID: 23794798      PMCID: PMC3686127          DOI: 10.4137/IDRT.S10652

Source DB:  PubMed          Journal:  Infect Dis (Auckl)        ISSN: 1178-6337


  18 in total

Review 1.  [Development of viral vectors and the application for viral entry mechanisms].

Authors:  Hideki Tani
Journal:  Uirusu       Date:  2011-06

2.  Virus budding/host interactions.

Authors:  Ronald N Harty; Anthony P Schmitt; Fadila Bouamr; Carolina B Lopez; Claude Krummenacher
Journal:  Adv Virol       Date:  2011-10-20

Review 3.  Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections.

Authors:  Thomas W Geisbert; Heinz Feldmann
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

Review 4.  Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization.

Authors:  Zhou Xing; Brian D Lichty
Journal:  Tuberculosis (Edinb)       Date:  2006-02-28       Impact factor: 3.131

Review 5.  Vesicular stomatitis virus as an oncolytic vector.

Authors:  Glen N Barber
Journal:  Viral Immunol       Date:  2004       Impact factor: 2.257

6.  Functional characterization of Ebola virus L-domains using VSV recombinants.

Authors:  Takashi Irie; Jillian M Licata; Ronald N Harty
Journal:  Virology       Date:  2005-06-05       Impact factor: 3.616

7.  Blood-feeding behavior of vesicular stomatitis virus infected Culicoides sonorensis (Diptera: Ceratopogonidae).

Authors:  Kristine E Bennett; Jessica E Hopper; Melissa A Stuart; Mark West; Barbara S Drolet
Journal:  J Med Entomol       Date:  2008-09       Impact factor: 2.278

Review 8.  Vesicular stomatitis virus: re-inventing the bullet.

Authors:  Brian D Lichty; Anthony T Power; David F Stojdl; John C Bell
Journal:  Trends Mol Med       Date:  2004-05       Impact factor: 11.951

9.  Modifications of the PSAP region of the matrix protein lead to attenuation of vesicular stomatitis virus in vitro and in vivo.

Authors:  Takashi Irie; Elena Carnero; Atsushi Okumura; Adolfo García-Sastre; Ronald N Harty
Journal:  J Gen Virol       Date:  2007-09       Impact factor: 3.891

Review 10.  Viral vectors for malaria vaccine development.

Authors:  Shengqiang Li; Emily Locke; Joseph Bruder; David Clarke; Denise L Doolan; Menzo J E Havenga; Adrian V S Hill; Peter Liljestrom; Thomas P Monath; Hussein Y Naim; Christian Ockenhouse; De-chu C Tang; Kent R Van Kampen; Jean-Francois Viret; Fidel Zavala; Filip Dubovsky
Journal:  Vaccine       Date:  2006-08-01       Impact factor: 3.641

View more
  2 in total

1.  Post-exposure treatment of Ebola virus using passive immunotherapy: proposal for a new strategy.

Authors:  Jean-Philippe Chippaux; Leslie V Boyer; Alejandro Alagón
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2015-02-15

2.  Interferon-γ Inhibits Ebola Virus Infection.

Authors:  Bethany A Rhein; Linda S Powers; Kai Rogers; Manu Anantpadma; Brajesh K Singh; Yasuteru Sakurai; Thomas Bair; Catherine Miller-Hunt; Patrick Sinn; Robert A Davey; Martha M Monick; Wendy Maury
Journal:  PLoS Pathog       Date:  2015-11-12       Impact factor: 6.823

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.